Westlake Therapeutics
PrivateLast Round
Series B
Jun 18, 2026
Total Funding Raised
$74.48M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Westlake Therapeutics operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series B round in June 2026.
Westlake Therapeutics is a biotechnology company that develops engineered red blood cell therapies for the treatment of cancer, autoimmune diseases, and metabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Westlake Therapeutics Comparables
Compare Westlake Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coastar Therapeutics | 83% | |
| Synth-Med Biotechnology Inc. | 83% | |
| Scarlet Therapeutics | 78% |
For institutional investors. Book with your work email.
Westlake Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 18, 2026 | ||||
| Series A Extension | Jun 25, 2022 | ||||
| Series A | Jul 15, 2021 | ||||
| Pre Seed | Jan 25, 2021 | ||||
| Pre Seed | Jun 2, 2020 |
For institutional investors. Book with your work email.
Westlake Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tasly Holding Group | Pre Seed |
| Eight Roads Ventures | Pre Seed, Series A |
| 西湖科创投 | Series A Extension, Pre Seed |
| Shaanxi Investment Group | Pre Seed |
| Westlake District's Science and Technology Direct Investment Fund | Pre Seed |
| HongShan Capital Group (HSG) | Series B, Pre Seed, Series A |
| Shenzhen Yifeng Investment Management Enterprise | Series B, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 50% MoM.
- Jun 18, 2026
$15M round led by HongShan Capital Group.
For institutional investors. Book with your work email.
Westlake Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Westlake Therapeutics's valuation, stock price, and market status.
Is Westlake Therapeutics a public or private company?
Westlake Therapeutics is a private company.
What is the current stock price of Westlake Therapeutics?
Westlake Therapeutics is a private company, so its shares have no public market price. Caplight tracks Westlake Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Westlake Therapeutics worth (valuation)?
Valuation information for Westlake Therapeutics is not publicly available.
Can I buy Westlake Therapeutics stock?
Westlake Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Westlake Therapeutics's last funding round?
Westlake Therapeutics's most recent funding round was Series B on June 18, 2026.
Who are the main investors in Westlake Therapeutics?
Key investors in Westlake Therapeutics include Westlake District's Science and Technology Direct Investment Fund, HongShan Capital Group (HSG), Shenzhen Yifeng Investment Management Enterprise.
Will Westlake Therapeutics IPO soon?
No public IPO plans have been announced for Westlake Therapeutics.
How can I track Westlake Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Westlake Therapeutics's shares on secondary markets.